The Netherlands Blocks Dr. Reddy’s Drug Shipment Bound For Brazil
This article was originally published in PharmAsia News
Dutch authorities seized a shipment of drugs from Dr. Reddy's Laboratories to Brazil, the first time a shipment of a major Indian drug maker has been seized for patent infringement. The drugs in the shipment were generics worth $500,000, composed primarily of losartan for treating high blood pressure and patented in The Netherlands by DuPont of U.S. as Cozaar. India's commerce secretary called the move an act of piracy and complained to the European Commission. Many shipments of small- and medium-sized Indian makers of bulk drugs had reported previous seizures by Dutch authorities of shipments bound for other countries. Indian lawyers argue the drugs are not destined for Dutch consumers and should not be blocked if they do not violate the patent laws of India or the nation of destination. (Click here for more
You may also be interested in...
Following the US request for ranitidine drugs to be withdrawn from the market, the European Medicines Agency says it would decide the fate of the products in the EU after wrapping up its own inquiry.
Perrigo will launch generics of GSK's OTC Voltaren Arthritis Pain drug later in 2020 following FDA approval of its ANDA. GSK, which received FDA's OTC switch approval in February, still hasn't launched the product or indicated when it will.
Kline & Company’s worst-case scenario – which it says is looking more and more likely – has the US cosmetics and personal-care market declining by as much as 8.1% in 2020. However, Kline, Mintel and other market intelligence firms say there are opportunities available to companies struggling to weather the COVID-19 storm.